Nov. 26, 2019—Eight Vanderbilt University faculty members have been named 2019 fellows of the American Association for the Advancement of Science, an honor bestowed upon AAAS members by their peers.
Oct. 18, 2019—Jeffrey Rathmell, Cornelius Vanderbilt Chair in Pathology, Microbiology and Immunology, will be a keynote speaker at the “Targeting Immunometabolism in Autoimmune Diseases and Inflammation” conference at The New York Academy of Sciences in New York City Oct. 22.
Nov. 1, 2018—Jeffrey Rathmell and colleagues show that a drug that inhibits glutamine metabolism — currently in clinical trials as an anticancer agent — might also be useful as a treatment for inflammatory and autoimmune diseases.
May. 10, 2018—W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
Nov. 10, 2016—At the intersection of immunology and metabolism is a burgeoning new field: immunometabolism. It’s an area where Vanderbilt has exceptional strengths, said Jeffrey Rathmell, Ph.D., Cornelius Vanderbilt Professor of Immunobiology.
May. 19, 2016—A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures.
Aug. 20, 2015—Jeffrey Rathmell, Ph.D., has been recruited to Vanderbilt University Medical Center (VUMC) to lead a new Center for Immunobiology, a structure supported by the Department of Pathology, Microbiology and Immunology, the Department of Medicine and Vanderbilt-Ingram Cancer Center (VICC).